Apixaban

PBAC's latest decision on Apixaban: Recommended with restriction (2015). Considered for Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE); and prevention of recurrent venous thromboembolism.

Eligible population

Adults with confirmed acute symptomatic deep vein thrombosis or pulmonary embolism for acute treatment; patients with history of acute symptomatic DVT or PE who have undergone at least 6 months therapy with apixaban for extended/continuing treatment and prevention of recurrent VTE.

Therapy area

Cardiovascular

Line of therapy

Any

Evidence base

RCT

Primary endpoint

Recurrent VTE or VTE-related death

Pivotal trial size

13,563 patients

Key trials

AMPLIFY, AMPLIFY-EXT, EINSTEIN-DVT, EINSTEIN-PE, EINSTEIN-EXT

Comparator

rivaroxaban

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis. No ICER calculated; submission based on cost-minimisation comparison to rivaroxaban.

Submission history

• Jul 2011: Recommended with restriction
• Nov 2012: Not recommended
• Mar 2013: Not recommended · Authority Required
• Mar 2015: Recommended with restriction · Authority Required

Similar precedents

• Rivaroxaban
  similarity 0.79
• Dabigatran etexilate
  similarity 0.78
• Enoxaparin
  similarity 0.73
• Warfarin
  similarity 0.69
• Enoxaparin sodium
  similarity 0.69
• Clopidogrel hydrogen sulfate
  similarity 0.65